Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (SYK). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Stryker Corp Narrows FY 2012 Revenue Guidance; Raises FY 2012 EPS Guidance; Issues FY 2013 EPS Guidance Below Analysts' Estimates-Conference Call
Stryker Corp narrowed fiscal 2012 sales range from 2%-5% to 2.5%-4%, underlying revenue growth excluding the impact of foreign currency and acquisitions. Fiscal 2012 adjusted earnings per share (EPS) is to be in the range of $4.04 to $4.07, up approximately 9% compared to prior target of double-digit year over year earnings growth. For fiscal 2013, it expects adjusted EPS in a range of $4.25 to $4.40, up approximately 5% to 8%, which includes an estimated $100 million impact from the medical device excise tax. Excluding the tax, the Company is targeting 9% to 12% EPS growth. The Company reported revenue of $8.307 billion in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $8.62 billion for fiscal 2012; EPS of $4.41 for fiscal 2013.
Latest Developments for Stryker Corp
- Stryker Corp Issues FY 2013 Guidance In Line With Analysts' Estimates-Conference Call
- Stryker Corp Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Gudiance-Conference Call
- Stryker Corp To Buy Hong Kong's Trauson Holdings Co Ltd For $764 Million-Reuters
- Stryker Corp Reaffirms FY 2012 EPS Guidance; Reaffirms FY 2013 Guidance-Conference Call
Latest Key Developments in Medical
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Urban Ag Corp Announces It Has Entered Into The Final Stages Of Negotiations To Acquire Contractor Currently Generating $4,500,000 In Revenues
- HeartWare International Inc Receives Conditional Approval From FDA To Enroll Supplemental Patient Cohort In Destination Therapy Trial
- Share this
- Link this
- Digg this


Follow Reuters